Drug intelligence / Profile preview

VSA-2 adjuvant

Development stage: Unknown
Lead developer: Adjuvax
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous, Intranasal

Overview

VSA-2 is a saponin-based vaccine adjuvant developed by Adjuvax and distributed in partnership with Croda. As a member of the VSA (Vaccine Saponin Adjuvant) family, it is designed to enhance the immunogenicity of vaccine antigens by stimulating both cellular and humoral immune responses. VSA-2 is specifically utilized in the development of both systemic and mucosal human vaccines. It functions by promoting the activation of antigen-presenting cells and modulating cytokine production, thereby improving the overall efficacy of the vaccine formulation. The product is currently available commercially for use in vaccine research and development.

Brand names: VSA-2VSA2VSA 2
Other names: VSA-2-Adjuvax-saponin adjuvantVSA2-Adjuvax-saponin adjuvantVSA 2-Adjuvax-saponin adjuvantVSA-2 adjuvantVSA2 adjuvantVSA 2 adjuvant

Beyond the preview

Go deeper on VSA-2 adjuvant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSA-2 adjuvant.

Explore the full profile